Study summary

Pirtobrutinib worked after earlier BTK inhibitors stopped working

BRUIN trial, WM group · 80 people with WM, phase 1/2 · Published May 2026, Lancet Haematology

82.5%response rate

What was tested

Pirtobrutinib, a non-covalent BTK inhibitor pill that still binds when the usual resistance mutation appears, for relapsed or refractory WM.

What they found

What it means

Gives a next step after ibrutinib, zanubrutinib or acalabrutinib.

Lancet Haematol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.